BridgeMD
New treatment option for Chronic Babesiosis
Official title B-FREE Chronic Babesiosis Study
ClinicalTrials.gov ID: NCT06656351
What this study is testing
What is Tafenoquine 100mg?
Tafenoquine 100mg is an investigational medicine, being studied as a potential treatment for chronic babesiosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female, aged ≥ 18 years
- Severe disabling fatigue
- Have at least one common symptom of babesiosis
- Have laboratory evidence of exposure to babesia in the last 12 months
- Able and willing to give written informed consent
You likely can't join if
- Glucose-6-phosphate-dehydrogenase (G6PD) deficiency
- Breastfeeding
- Unmanaged Psychotic disorder
- Known hypersensitivity reaction to tafenoquine or other 8-aminoquinolines
- Current or planned treatment with quinine
- Uncontrolled cardiopulmonary or endocrine disorders
See the full eligibility criteria
- Male or female, aged ≥ 18 years
- Severe disabling fatigue
- Have at least one common symptom of babesiosis
- Have laboratory evidence of exposure to babesia in the last 12 months
- Able and willing to give written informed consent
- Able and willing to perform all study assessments
- If female negative urine pregnancy test and
- If female agree to use an acceptable method of birth control
- Glucose-6-phosphate-dehydrogenase (G6PD) deficiency
- Breastfeeding
- Unmanaged Psychotic disorder
- Known hypersensitivity reaction to tafenoquine or other 8-aminoquinolines
- Current or planned treatment with quinine
- Uncontrolled cardiopulmonary or endocrine disorders
- Taking OCT2/MATE substrates without appropriate medical oversight
- Medical history of chronic, active viral diseases including HIV/AIDS, hepatitis B, and hepatitis C
- Have a risk factors for relapsing babesiosis
- Anorexia
- Any concomitant significant illness unrelated to babesiosis
- The patient is unable to tolerate medication by the oral route
- The patient has previously taken tafenoquine
- Hemoglobin at baseline is ≤ 8 g/dL
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.